Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections

Médecine et maladies infectieuses
F IsnardG Deray

Abstract

The authors had for aim to define the threshold of nephrotoxicity before switching to other antifungal treatment in hematological patients treated by conventional amphotericin B (AmB) as an empiric antifungal treatment. A prospective randomised multicenter study was made on 32 neutropenic hematological patients receiving conventional AmB for empirical antifungal treatment. The patients were randomised after a greater than or equal to 30% increase of serum creatinine (sCr). Patients in the early-switch group received liposomal AmB just after randomisation and patients in the late-switch group received liposomal AmB only when serum creatinine increase was greater or equal to 100% or sCr reached 170mumol/L. Thirty-one patients were analysed: 16 patients in the early-switch group and 15 patients in the late-switch group (seven switched to liposomal AmB and eight continued conventional AmB treatment). The mean age of patients was 48 years and 68% were men. The most frequent underlying haematological malignancy was acute leukemia (94%). In the late-switch group, the degradation of renal function continued after randomisation contrary to the early-switch group: median variations of calculated sCr clearance in early- and late-switch gr...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·F MeunierO Ringdén
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J R WingardJ Lister
Mar 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D W BatesR Platt
Dec 4, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AsciogluUNKNOWN Mycoses Study Group of the National Institute of Allergy and Infectious Diseases
Jan 22, 2002·The Journal of Antimicrobial Chemotherapy·Gilbert Deray
Jul 29, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis Ostrosky-ZeichnerStuart H Cohen
Jul 14, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew J UllmannUNKNOWN Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators

❮ Previous
Next ❯

Citations

Nov 26, 2015·The Cochrane Database of Systematic Reviews·Juan Pablo Botero Aguirre, Alejandra Maria Restrepo Hamid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Related Papers

International Journal of Antimicrobial Agents
W V Kern
© 2021 Meta ULC. All rights reserved